- Home
- OTLK vs TURN Comparison
OTLK vs TURN Comparison
Compare OTLK & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- TURN
- Stock Information
- Founded
- OTLK 2010
- TURN 1981
- Country
- OTLK United States
- TURN United States
- Employees
- OTLK N/A
- TURN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- TURN Finance/Investors Services
- Sector
- OTLK Health Care
- TURN Finance
- Exchange
- OTLK Nasdaq
- TURN Nasdaq
- Market Cap
- OTLK 48.3M
- TURN 39.9M
- IPO Year
- OTLK 2016
- TURN N/A
- Fundamental
- Price
- OTLK $1.57
- TURN $4.00
- Analyst Decision
- OTLK Strong Buy
- TURN
- Analyst Count
- OTLK 5
- TURN 0
- Target Price
- OTLK $9.60
- TURN N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- TURN 17.4K
- Earning Date
- OTLK 08-13-2025
- TURN 01-01-0001
- Dividend Yield
- OTLK N/A
- TURN N/A
- EPS Growth
- OTLK N/A
- TURN N/A
- EPS
- OTLK 0.83
- TURN N/A
- Revenue
- OTLK N/A
- TURN $194,813.00
- Revenue This Year
- OTLK N/A
- TURN N/A
- Revenue Next Year
- OTLK $379.84
- TURN N/A
- P/E Ratio
- OTLK $1.91
- TURN N/A
- Revenue Growth
- OTLK N/A
- TURN 254.25
- 52 Week Low
- OTLK $0.87
- TURN $3.12
- 52 Week High
- OTLK $9.25
- TURN $4.25
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- TURN 55.14
- Support Level
- OTLK $1.65
- TURN $3.93
- Resistance Level
- OTLK $2.04
- TURN $4.01
- Average True Range (ATR)
- OTLK 0.12
- TURN 0.06
- MACD
- OTLK -0.03
- TURN 0.00
- Stochastic Oscillator
- OTLK 2.13
- TURN 84.21
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.